Answers are grounded in this paper and cite their sources.
Levels of serum sIL-2R (soluble interleukin-2 receptor) reflect the total amount of activated T lymphocytes in tumor infiltrating lymphocytes of cancer tissues and metastatic organs, because a part of alpha-chain of IL-2R is released into the bloodstream on the attachment of IL-2 (interleukin-2) to its specific IL-2R membrane. In most malignant diseases, elevated levels of serum sIL-2R are found, compare to normal control. Serum sIL-2R is a useful parameter for evaluating the disease stage and monitoring the disease progression during the post-treatment follow-up, though it is not an organ-specific parameter.
No takes yet. Share an insight, caveat, or question.
Saburo Murakami (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: